Abstract
BackgroundZetomipzomib, a first-in-class selective inhibitor of the immunoproteasome blocks multiple pathways involved in inflammatory cytokine production and immune effector cell activity – including macrophages, B cells and T cells leading...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
